Oil-in-water adjuvants (squalene) have not been licensed in the U.S., although they are used in some inactivated vaccines marketed in Europe and other countries (live virus vaccines do not contain adjuvants). Many inactivated vaccines in the U.S. contain licensed aluminum-based adjuvants added to increase production of antibodies in an effort to make vaccines more effective at preventing infection.
Oil-based adjuvants (MF-59 and AS03) manipulate and hyper-stimulate the immune system to mount a stronger immune response to the lab-altered virus or bacteria contained in vaccines. However, the use of squalene type vaccine adjuvants, which were allegedly added to experimental anthrax vaccines and made Gulf War soldiers sick, is controversial.
Oil based adjuvants may increase the risk for vaccine-induced chronic inflammation and autoimmunity in some children and adults genetically predisposed to atypical inflammatory responses and autoimmunity. No published scientific studies have examined whether those already suffering with chronic inflammation associated with brain and immune system dysfunction may be at special risk.
U.S. health officials are expected to by-pass normal FDA licensing procedures and include oil-in-water adjuvants in some swine flu vaccines released for public use. The legal ability for the FDA to approve unlicensed vaccines and drugs whenever a national “public health emergency” has been declared was given to the FDA by Congress under an Emergency Use Authorization (EUA) provision included in 2004 Project Bioshield legislation (see below for more information on Bioshield and the EUA).